EPHX3
Epoxide hydrolase 3
Also known as: ABHD9, EPHX3_HUMAN, FLJ22408
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9H6B9
- Gene
- EPHX3
- Ensembl
- ENSG00000105131
- Chromosome
- 19
- Canonical length
- 360 aa
- Protein class
- Enzymes, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
Enables epoxide hydrolase activity. Involved in epoxide metabolic process. Located in intracellular membrane-bounded organelle and membrane. [provided by Alliance of Genome Resources, Apr 2025]
Canonical amino-acid sequenceUniProt
360 residues, UniProt reviewed canonical sequence.
>Q9H6B9|EPHX3
1 MPELVVTALL APSRLSLKLL RAFMWSLVFS VALVAAAVYG CIALTHVLCR PRRGCCGRRR
61 SASPACLSDP SLGEHGFLNL KSSGLRLHYV SAGRGNGPLM LFLHGFPENW FSWRYQLREF
121 QSRFHVVAVD LRGYGPSDAP RDVDCYTIDL LLVDIKDVIL GLGYSKCILV AHDWGALLAW
181 HFSIYYPSLV ERMVVVSGAP MSVYQDYSLH HISQFFRSHY MFLFQLPWLP EKLLSMSDFQ
241 ILKTTLTHRK TGIPCLTPSE LEAFLYNFSQ PGGLTGPLNY YRNLFRNFPL EPQELTTPTL
301 LLWGEKDTYL ELGLVEAIGS RFVPGRLEAH ILPGIGHWIP QSNPQEMHQY MWAFLQDLLDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against EPHX3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 74 nTPM
Expression across tissuesHPA
Tissue
- skin: 74 nTPM
- esophagus: 66 nTPM
- vagina: 35 nTPM
- cervix: 26 nTPM
- tonsil: 25 nTPM
- urinary bladder: 8.1 nTPM
Single-cell type
- esophageal apical cells: 607 nCPM
- esophageal suprabasal cells: 199 nCPM
- suprabasal keratinocytes: 77 nCPM
- esophageal basal cells: 44 nCPM
- urothelial cells: 23 nCPM
- submucosal glandular cells: 22 nCPM
Immune cell
- non-classical monocyte: 2.4 nTPM
- intermediate monocyte: 1.9 nTPM
- plasmacytoid DC: 1.3 nTPM
- classical monocyte: 0.5 nTPM
- total PBMC: 0.2 nTPM
- myeloid DC: 0.1 nTPM
Brain region
- hypothalamus: 0.8 nTPM
- medulla oblongata: 0.8 nTPM
- cerebral cortex: 0.7 nTPM
- midbrain: 0.6 nTPM
- pons: 0.6 nTPM
- white matter: 0.6 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.66
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.03
- DepMap mean gene effect
- 0.04
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads EPHX3 as an antibody target. Whether an autoantibody or antibody against EPHX3 could matter depends on whether native EPHX3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
EPHX3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label EPHX3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...